TWYNSTA

GENERAL CONSIDERATIONS
Telmisartan is an effective treatment of hypertension in once-daily doses of 20-80 mg while amlodipine is effective in doses of 2.5-10 mg.

• Dosage must be individualized and may be increased after at least 2 weeks.
• Most of the antihypertensive effect is apparent within 2 weeks, and maximal reduction is generally attained after 4 weeks.
• The maximum recommended dose of TWYNSTA tablets is 80/10 mg once daily.
• The adverse reactions of telmisartan are uncommon and independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily peripheral edema) and dose-independent phenomena, the former much more common than the latter. Visit the Safety Section to learn more.
• TWYNSTA may be taken with or without food.

Close

REPLACEMENT THERAPY
Patients receiving amlodipine and telmisartan from separate tablets may instead receive TWYNSTA tablets containing the same component doses once daily.

• When substituting for individual components, increase the dose of TWYNSTA if blood pressure control has not been satisfactory.

Close

ADD-ON THERAPY FOR PATIENTS WITH HYPERTENSION NOT ADEQUATELY CONTROLLED ON ANTIHYPERTENSIVE MONOTHERAPY
TWYNSTA tablets may be used to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with telmisartan (or another angiotensin receptor blocker) alone.

• Patients treated with 10 mg amlodipine who experience any dose-limiting adverse reactions such as edema may be switched to TWYNSTA 40/5 mg tablets once daily, reducing the dose of amlodipine without reducing the overall expected antihypertensive response. Visit the Safety Section to learn more.

Close

INITIAL THERAPY
A patient may be initiated on TWYNSTA tablets if it is unlikely that control of blood pressure would be achieved with a single agent.

• The usual starting dose of TWYNSTA is 40/5 mg once daily. Patients requiring larger blood pressure reductions may be started on TWYNSTA 80/5 mg tablets once daily.
• Initial therapy with TWYNSTA is not recommended in patients 75 years of age or older or in patients with hepatic impairment.
• Correct imbalances of intravascular volume or salt-depletion before initiating therapy with TWYNSTA tablets.

Close

DOSING IN SPECIFIC POPULATIONS

• Renal impairment: No initial dosage adjustment is required for patients with mild or moderate renal impairment. Titrate slowly in patients with severe renal impairment.
• Hepatic impairment: In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients with hepatic impairment.
• Patients 75 years of age and older: In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years of age and older.

Close